EMN

Eastman Chemical Company: Q3 2007 10-Q Summary

Business Context and Reporting Period

This filing is a Quarterly Report on Form 10-Q for Eastman Chemical Company for the period ended September 30, 2007. The Company operates in five segments: Coatings, Adhesives, Specialty Polymers and Inks (CASPI); Fibers; Performance Chemicals and Intermediates (PCI); Performance Polymers; and Specialty Plastics (SP). The reporting period is characterized by significant strategic restructuring, specifically the divestiture of underperforming polyethylene terephthalate (PET) manufacturing facilities in Latin America and Europe.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Sales decreased 8% in Q3 and 3% for the first nine months compared to the prior year. This decline is primarily attributed to the divestiture of product lines (Polyethylene and Epolene) in late 2006 and the sale of the San Roque, Spain PET facility in Q2 2007.
• Profitability Impact: Operating earnings dropped 75% in Q3 and 36% for the nine-month period. The primary driver was $120 million in asset impairments and restructuring charges in Q3 (and $143 million for the nine months), largely related to the write-down of PET assets in Mexico and Argentina held for sale.
• Non-GAAP Performance: Excluding accelerated depreciation and asset impairments, operating earnings were relatively stable, at $169 million for Q3 2007 versus $171 million for Q3 2006.
• Cash Flow: Operating cash flow improved significantly to $411 million for the first nine months of 2007, compared to $233 million in the same period of 2006, driven by strong earnings and normalized working capital levels.

Guidance, Outlook, and Risks

• Strategic Actions: The Company entered definitive agreements to sell PET facilities in Mexico and Argentina. It also completed the sale of its Spain PET facility. Management expects to continue rationalizing capacity in North America and pursuing options for remaining European PET facilities.
• 2007 Outlook:
  • Capital expenditures expected to reach approximately $500 million.
  • Accelerated depreciation costs expected to total approximately $50 million for the full year.
  • Effective tax rate expected to be approximately 34%.
  • Net interest expense expected to decrease due to higher interest income from cash balances.
• Share Repurchases: The Company completed a $300 million share repurchase program in Q3. In October 2007, the Board authorized an additional $700 million for repurchases.
• Risks: Key risks include volatility in raw material and energy costs, foreign currency exchange rate fluctuations, and the execution of strategic divestitures. Legal proceedings regarding sorbates and asbestos are ongoing but are not expected to have a material adverse effect.

Investor Verification Checklist

• Divestiture Timing: Verify the closing dates and final proceeds for the Mexico and Argentina PET facility sales, as these are currently "held for sale" and subject to customary approvals.
• Impairment Details: Review the specific valuation assumptions used for the $117 million impairment charge on Latin American assets to ensure they reflect fair market value less cost to sell.
• Working Capital Trends: Monitor receivables and inventory levels to ensure the "normalized" working capital position cited in the cash flow discussion is sustainable.
• Raw Material Costs: Assess the Company's ability to pass on increased raw material and energy costs to customers, as this remains a primary driver of gross margin volatility.
• Capital Allocation: Track the execution of the new $700 million share repurchase authorization and the $500 million capital expenditure plan, particularly regarding the IntegRex technology expansion.